Acción EPRSQ EPIRUS BIOPHARMACEUTICALS, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas EPIRUS Biopharmaceuticals, Inc.

Acciones

EPRSQ

US29428P1075

Mercado cerrado - OTC Markets
Otros sitios de cotización
 20:34:32 06/02/2024 		Varia. Cinco días. Varia. 1 de enero.
0,000001 USD -.--% Gráfico intradía de EPIRUS Biopharmaceuticals, Inc. -.--% -.--%
2016 Transcript : EPIRUS Biopharmaceuticals, Inc., Q4 2015 Earnings Call, Mar 15, 2016
2015 Transcript : EPIRUS Biopharmaceuticals, Inc., Q3 2015 Earnings Call, Nov 16, 2015

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.
Praxis Precision Medicines, Inc. completed the acquisition of Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q).
Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.
Praxis Precision Medicines, Inc. agreed to acquire Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q) for $1 million.
Notice of Intent of Asset Sale Filed by EPIRUS Biopharmaceuticals, Inc.
Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.
EPIRUS Biopharmaceuticals, Inc.(OTCPK:EPRS.Q) dropped from S&P TMI Index
EPIRUS Biopharmaceuticals, Inc.(OTCPK:EPRS.Q) dropped from NASDAQ Composite Index
EPIRUS Biopharmaceuticals, Inc. Announces Management Resignations
EPIRUS Biopharmaceuticals, Inc. Filed for Bankruptcy
EPIRUS Biopharmaceuticals, Inc. Announces Executive Termination
Polpharma S.A. completed the acquisition of EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc..
Polpharma S.A. entered into a binding term sheet to acquire EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc. for $3.5 million.
EPIRUS Biopharmaceuticals, Inc. Announces Executive Changes
EPIRUS Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
EPIRUS Biopharmaceuticals, Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2015
EPIRUS Biopharmaceuticals, Inc. Initiates Pivotal Global Phase 3 Clinical Study for BOW015 (Infliximab Biosimilar)
EPIRUS Biopharmaceuticals, Inc Provides Clinical Program Update on BOW015
EPIRUS Biopharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015
EPIRUS Biopharmaceuticals, Inc. Appoints Vincent E. Aurentz as Chief Business Officer
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción EPRSQ
  4. Noticias EPIRUS Biopharmaceuticals, Inc.
  5. Otros idiomas